Scott Giacobello Sells 77,000 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock

Key Points

• CFO Scott Giacobello sold 77,000 shares on April 15 at an average price of $3.86 for proceeds of $297,220, reducing his stake by 14.99% to 436,824 shares; the sale was disclosed in an SEC filing and was made to cover tax withholding on vested equity.
• WHWK traded down 2.8% to $4.11 on heavy volume (571,343 vs. avg. 169,490), with a 50-day/200-day moving average of $3.43/$2.77, a 1‑year range of $1.39–$4.48, market cap of about $194M and a P/E of 8.74.
• Analysts show a "Moderate Buy" consensus with an average target of $7.00, based on four Buy ratings, one Hold and one Sell, and several recent Buy/Outperform coverage initiations.

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) CFO Scott Giacobello sold 77,000 shares of the company's stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $3.86, for a total transaction of $297,220.00. Following the completion of the sale, the chief financial officer owned 436,824 shares of the company's stock, valued at approximately $1,686,140.64. This trade represents a 14.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Whitehawk Therapeutics Trading Down 2.8%

WHWK stock traded down $0.12 on Friday, hitting $4.11. The company's stock had a trading volume of 571,343 shares, compared to its average volume of 169,490. The firm has a 50 day moving average of $3.43 and a two-hundred day moving average of $2.77. Whitehawk Therapeutics, Inc. has a 1 year low of $1.39 and a 1 year high of $4.48. The stock has a market cap of $193.99 million, a price-to-earnings ratio of 8.74 and a beta of 0.57.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.21.

Hedge Funds Weigh In On Whitehawk Therapeutics

Institutional investors have recently bought and sold shares of the company. Quadrature Capital Ltd acquired a new position in Whitehawk Therapeutics in the 4th quarter valued at $28,000. ABG Innovation Capital Partners III GP Ltd acquired a new position in shares of Whitehawk Therapeutics during the 3rd quarter worth $51,000. Dimensional Fund Advisors LP acquired a new position in shares of Whitehawk Therapeutics during the 3rd quarter worth $84,000. Marshall Wace LLP acquired a new position in shares of Whitehawk Therapeutics during the 4th quarter worth $164,000. Finally, Jane Street Group LLC grew its stake in shares of Whitehawk Therapeutics by 177.3% during the 4th quarter. Jane Street Group LLC now owns 69,931 shares of the company's stock worth $169,000 after purchasing an additional 44,716 shares during the period. 52.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

WHWK has been the subject of several research reports. Citigroup started coverage on shares of Whitehawk Therapeutics in a research report on Thursday. They issued an "outperform" rating for the company. JonesTrading started coverage on shares of Whitehawk Therapeutics in a research note on Monday, December 22nd. They issued a "buy" rating and a $7.00 price objective on the stock. Oppenheimer started coverage on shares of Whitehawk Therapeutics in a research note on Thursday, February 5th. They issued an "outperform" rating and a $6.00 price objective on the stock. Citizens Jmp started coverage on shares of Whitehawk Therapeutics in a research note on Thursday. They issued a "market outperform" rating and a $8.00 price objective on the stock. Finally, Wall Street Zen cut shares of Whitehawk Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, April 11th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Whitehawk Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $7.00.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.